Browsing by Author "Visa Turmo, Laura"

Sort by: Order: Results:

  • Visa Turmo, Laura; Carmona-Bayonas, Alberto; AGAMENON Study Group (Elsevier, 2018)
    OBJECTIVE: Advanced gastric cancer (AGC) is a common neoplasm in older adults. Nevertheless, there are few specific management data in the literature. The aim of this study was to assess non-inferiority of survival and ...
  • Gironés, R.; Visa Turmo, Laura; Pi-Figueras Valls, María; Spanish Working Group on Geriatric Oncology of the Spanish Society of Medical Oncology (SEOM) (SpringerOpen, 2018)
    INTRODUCTION: Geriatric oncology (GO) is a discipline that focuses on the management of elderly patients with cancer. The Spanish Society of Medical Oncology (SEOM) created a Working group dedicated to geriatric oncology ...
  • Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...
  • Martínez Bosch, Neus; Barranco Priego, Luis Eugenio; Orozco, Carlos Alberto; Moreno, Mireia; Visa Turmo, Laura; Iglesias Coma, Mar; Oldfield, Lucy; Neoptolemos, John P.; Greenhalf, William; Earl, Julie; Carrato, Alfredo; Costello, Eithne; Navarro Medrano, Pilar (Impact Journal, 2018)
    Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that ...
  • Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...